Research Summary: Ascites May Help Ovarian Cancer Spread — and an Older Cholesterol Drug Could Help Disrupt It
- 11 hours ago
- 2 min read
Setayeshpour, Y., Chen, SY., Dayanidhi, D.L. et al. Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. Nat Commun 17, 4190 (2026). https://doi.org/10.1038/s41467-026-72116-1
A newly published study in Nature Communications sheds light on an important question in ovarian cancer research: why ovarian cancer cells are often able to survive and spread throughout the abdominal cavity.
Researchers from Duke University School of Medicine found that ascites — the buildup of fluid in the abdomen that commonly occurs in advanced ovarian cancer — may actively help cancer cells survive and metastasize. Their findings also suggest that a decades-old cholesterol medication may help weaken this protective effect.
What Is Ascites?
Ascites is a buildup of fluid in the abdomen that affects many patients with advanced ovarian cancer. It can cause symptoms including:
Abdominal swelling and discomfort
Difficulty breathing
Reduced mobility
Pain and pressure
Until now, ascites has often been viewed primarily as a symptom of advanced disease. However, this new research suggests that the fluid itself may play a more active role in helping cancer spread.
What the Researchers Found
The study discovered that ascites appears to protect ovarian cancer cells from a type of cell death called ferroptosis.
Ferroptosis occurs when iron inside cells reacts with certain fats, causing damage to the cell membrane and ultimately leading to cell death. Floating metastatic cancer cells are normally vulnerable to this process.
However, researchers found that fluid from ascites changes how ovarian cancer cells process fats and iron, allowing them to avoid ferroptosis and survive longer within the abdominal cavity.
Importantly, the protective effect appeared to come largely from the lipid (fat) content within the ascites fluid.
A Potential Role for an Existing Cholesterol Drug
Researchers also explored whether altering lipid metabolism could make cancer cells more vulnerable again.
They tested bezafibrate, an older cholesterol-lowering medication commonly used to reduce triglycerides. In laboratory models, the drug appeared to restore the cancer cells’ sensitivity to ferroptosis — but only in the presence of ascites.
The medication did not directly kill cancer cells on its own. Instead, the findings suggest it may interfere with the supportive environment that ascites creates around tumors.
While the research is still early and has not yet shown that bezafibrate can treat ovarian cancer in patients, the study highlights an emerging area of cancer research: targeting the tumor environment, not just the tumor itself.
Why This Matters
Ovarian cancer frequently spreads throughout the abdominal cavity, and ascites is present in approximately 90% of patients with advanced disease.
Understanding how ascites helps cancer cells survive may open the door to:
New therapeutic strategies
Improved approaches to metastatic ovarian cancer
Combination treatments that make cancer cells more sensitive to existing therapies
Repurposing existing medications for supportive cancer treatment research
Researchers also noted that these findings could have broader implications for other abdominal cancers, including colorectal and pancreatic cancers, which can also spread within the abdominal cavity.
Important Takeaway for Patients
This study represents promising early-stage laboratory research. More studies and clinical trials will be needed before any treatment changes occur.
Patients should not start, stop, or change medications based on this research alone and should always speak with their healthcare team regarding treatment decisions.